NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDFluorouracil  Malignant disease and immunosuppression, Antimetabolites, 08.01.03
GREENFluorouracil 5% cream Efudix® Skin, Photodamage, 13.08.01
GREENSalicylic acid, fluorouracil cutaneous solution Actikerall® Skin, Photodamage, 13.08.01
REDUridine Triacetate Vistogard®
(10g Oral Granules) 		Malignant disease and immunosuppression, Drugs for cytotoxic-induced side-effects, 08.01
Non Formulary items found
Status Description Section
 Fluorouracil  Eye, Cytotoxics / wound healing modulators, 11.99.99.99
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Fluorouracil Fluorouracil Malignant Disease, Cytotoxic Responsive Malignancy, Antineoplastic Drugs Antimetabolites
Fluorouracil Fluorouracil Skin, Sun Protection And Photodamage, Antineoplastic Drugs Antimetabolites
Fluorouracil Fluorouracil With Salicylic Acid Skin, Sun Protection And Photodamage
Fluorouracil Fluorouracil With Salicylic Acid Skin, Sun Protection And Photodamage, Antineoplastic Drugs Antimetabolites
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
Clinical Commissioning Urgent Policy Statement: Uridine triacetate for the treatment of patients exhibiting earlyonset severe toxicities following 5-fluorouracil or capecitabine administration (all ages)
MHRA Drug Safety update (October 2020): 5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity
NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy